Edvince Overview

  • Founded

  • 2003

Founded
  • Status

  • Private

  • Employees

  • 2

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $651K

  • Investors

  • 6

Edvince General Information

Description

Developer of a medical drug designed to minimize the chances of brain injuries arising out of a stroke. The company's drug is focused on a new acute stroke therapy that identifies underlying factors and symptoms of stroke, enabling patients to minimize brain damage in different types of stroke.

Contact Information

Website
www.edvince.com
Formerly Known As
Pronas Pharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Medicon Village, Scheelevägen 2
  • 223 81 Lund
  • Sweden
+46 0000000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Edvince Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 16-Dec-2016 $651K 00000 Completed Generating Revenue
2. Accelerator/Incubator 02-Sep-2016 Completed Generating Revenue
1. Corporate 01-Jan-2007 Completed Startup
To view Edvince’s complete valuation and funding history, request access »

Edvince Patents

  • 16

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Edvince Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220273660-A1 Mek inhibitor for treatment of stroke Pending 30-Jul-2019 0000000000
AU-2020323687-A1 Mek inhibitor for treatment of stroke Pending 30-Jul-2019 0000000000
EP-4003356-A1 Mek inhibitor for treatment of stroke Pending 30-Jul-2019 0000000000
CA-3146052-A1 Mek inhibitor for treatment of stroke Pending 30-Jul-2019 0000000000
GB-201908003-D0 Pharmaceutical composition Inactive 05-Jun-2019
To view Edvince’s complete patent history, request access »

Edvince Executive Team (5)

Name Title Board Seat Contact Info
Tore Duvold Chief Executive Officer, Managing Director & Board Member
Lars Edvinsson Founder, CSO & Board Member
Peter Andersen Chairman
Stine Larsen Chief Medical Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Edvince Board Members (9)

Name Representing Role Since
Jesper Kihl Self Board Member 000 0000
Johanna Adami Ph.D Self Board Member 000 0000
Lars Edvinsson Edvince Founder, CSO & Board Member 000 0000
Martin Moller Self Board Member 000 0000
Peter Andersen Edvince Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Edvince Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Edvince Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Almi Invest Venture Capital Minority 000 0000 000000 0
EBD Group Corporation Minority 000 0000 000000 0
LMK Forward Venture Capital Minority 000 0000 000000 0
Swedish Growth Fund Venture Capital Minority 000 0000 000000 0
SmiLe Incubator Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial